LN-145 + Cyclophosphamide + Fludarabine + Interleukin-2

Phase 2Recruiting

2 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cutaneous Squamous Cell Carcinoma

Conditions

Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma, Skin Cancer

Trial Timeline

Feb 10, 2026 → Jun 29, 2029

NCT ID

NCT07288073

About LN-145 + Cyclophosphamide + Fludarabine + Interleukin-2

LN-145 + Cyclophosphamide + Fludarabine + Interleukin-2 is a phase 2 stage product being developed by Iovance Biotherapeutics for Cutaneous Squamous Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07288073. Target conditions include Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma.

What happened to similar drugs?

7 of 20 similar drugs in Cutaneous Squamous Cell Carcinoma were approved

Approved (7) Terminated (1) Active (12)

✅ONTAK (denileukin difitox, DAB389IL-2)EisaiApproved

✅ONTAKEisaiApproved

✅MogamulizumabKyowa KirinApproved

✅Clopidogrel + TicagrelorAstraZenecaApproved

✅Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Normal Saline (Placebo)NovartisApproved

✅BexaroteneBausch HealthApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07288073	Phase 2	Recruiting	Feb 10, 2026	Jun 29, 2029	Cutaneous Squamous Cell Carcinoma

Competing Products

20 competing products in Cutaneous Squamous Cell Carcinoma

See all competitors

Product	Company	Stage	Hype Score
ONTAK (denileukin difitox, DAB389IL-2)	Eisai	Approved	43
ONTAK	Eisai	Approved	43
E7777 9 mcg/kg	Eisai	Phase 3	40
ONTAK	Eisai	Approved	43
Mogamulizumab	Kyowa Kirin	Approved	47
Mogamulizumab + Brentuximab vedotin	Kyowa Kirin	Phase 1	36
Mogamulizumab	Kyowa Kirin	Phase 2	39
KW-0761 + Vorinostat	Kyowa Kirin	Phase 3	40
Enzastaurin	Eli Lilly	Phase 2	35
Clopidogrel + Ticagrelor	AstraZeneca	Approved	43
Pembrolizumab	Merck	Phase 2	42
Comparator: vorinostat	Merck	Pre-clinical	26
Pembrolizumab	Merck	Phase 2	39
TR701 FA	Merck	Phase 2	35
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months	Merck	Phase 2	35
Pembrolizumab	Merck	Phase 2	42
Tulisokibart + Placebo	Merck	Phase 2	39
Aspirin + Ipilimumab + Pembrolizumab	Merck	Phase 2	35
Pembrolizumab + Mogamulizumab	Merck	Phase 2	42
TR-701 FA + Linezolid	Merck	Phase 3	40